ADMA Biologics Reports Strong Q4 2025 Earnings and Positive Outlook

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 5 days ago

0mins

ADMA+6.49%

Should l Buy ADMA?

Source: seekingalpha

Significant Revenue Growth: ADMA achieved total revenue of $510 million in 2025, with adjusted EBITDA at $231 million and net income reaching $161 million, reflecting strong execution across its commercial and financial platforms, which is expected to lay a solid foundation for future market expansion.
ASCENIV Driving Growth: ASCENIV contributed $363 million in net revenue for 2025, marking a 51% year-over-year growth, and is anticipated to continue driving market penetration in 2026, further enhancing the company's competitiveness and profitability.
Cash Flow Improvement Expected: ADMA ended 2025 with $88 million in cash, and expects significant cash generation improvements in 2026 due to higher margins and improved working capital, supporting the company's ongoing growth strategy.
Leadership Change and Strategic Direction: Incoming CFO Terry Kohler will focus on optimizing working capital and financial execution, and with continued investment in ASCENIV, ADMA is projected to exceed $635 million in revenue in the coming years, showcasing strong growth potential.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ADMA

About ADMA

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ADMA Biologics Announces $200 Million Capital Return Initiative

20 hours agoseekingalpha

Capital Return Initiative: ADMA Biologics has announced a capital return initiative targeting approximately $200 million in 2026, including a $125 million accelerated share repurchase agreement with JPMorgan, highlighting the company's commitment to enhancing shareholder value.
Repurchase Agreement Details: Under the ASR agreement, ADMA will pay JPMorgan an upfront amount of $125 million and is expected to initially receive about 6.4 million shares of common stock around March 3, 2026, representing approximately 80% of the anticipated repurchased shares, reflecting confidence in the current stock price.
Progress on Buyback Program: Since the authorization of the buyback program in May 2025, ADMA has repurchased approximately $160 million of its common stock, indicating a disciplined and opportunistic approach to capital allocation aimed at enhancing long-term shareholder value.
Future Outlook: ADMA forecasts revenue of $635 million for 2026, as ASCENIV drives margin expansion and new supply agreements extend the growth runway, positioning the company for continued success.

ADMA Biologics (ADMA) Q4 2025 Earnings Transcript

3 days agoNASDAQ.COM

ADMA Biologics Reports Strong 2025 Financial Results

3 days agoYahoo Finance

Significant Revenue Growth: ADMA Biologics reported total revenue of $510 million for 2025, reflecting a 20% year-over-year increase, demonstrating the company's disciplined execution across its commercial and financial platforms, which enhances market confidence and investor expectations.
Substantial EBITDA Increase: The adjusted EBITDA for 2025 reached $231 million, a 40% year-over-year growth, indicating ongoing improvements in operational leverage and cost management, further solidifying the company's profitability.
Strong Ascentive Product Performance: Ascentive achieved net revenue of $363 million in 2025, marking a 51% year-over-year increase, driven by robust demand and widespread physician adoption of its patented immune globulin, indicating significant growth potential ahead.
Leadership Transition and Strategic Adjustments: CFO Brad Tade announced his retirement, with Terry Kohler stepping in, bringing extensive public company experience that is expected to further optimize capital efficiency and cash flow, supporting the company's long-term growth strategy.